Bioretec Ltd’s Half-year report 2026: H1 close signals momentum

ViewReleaseInStandardHtml

Bioretec Ltd’s Half-year report 2026: H1 close signals momentum

Bioretec Ltd. | Company announcement | 13 August 2026 at 9:00 a.m.

This announcement summarizes Bioretec Ltd’s half-year report for January–June 2026. The complete half-year report is attached to this release as a PDF file and available on the company’s website at https://investors.bioretec.com/en/reports_and_presentations. The half-year report is unaudited.

April–June 2026 in brief

• Net sales amounted to EUR 1,100 thousand (4–6/2025: EUR 678 thousand)

• Adjusted sales margin was 68.0% (57.1%) of net sales

• EBITDA was EUR -2,251 (-3,321) thousand

• The result for the reporting period amounted to EUR -3,307 (-4,330) thousand

January–June 2026 in brief

• Net sales amounted to EUR 2,320 thousand (1–6/2025: EUR 2,074 thousand)

• Adjusted sales margin was 69.2% (56.8%) of net sales

• EBITDA was EUR -3,625 (-4,557) thousand

• The result for the reporting period amounted to EUR -4,678 (-5,628) thousand

Key figures

EUR 1,000 unless otherwise indicated	4–6/2026	4–6/2025	Change, %	1–6/2026	1–6/2025	Change, %	1–12/2025
Net sales	1,100	678	62.2%	2,320	2,074	11.9%	3,522
Adjusted sales margin, % of net sales1	68.0%	57.1%		69.2%	56.8%		59.3%
EBITDA	-2,251	-3,321		-3,625	-4,557		-8,476
EBIT	-2,311	-3,373		-3,746	-4,660		-8,686
EBIT, % of net sales	-210.1%	-497.8%		-161.5%	-224.7%		-246.6%
Profit / loss for the period	-3,307	-4,330		-4,678	-5,628		-9,483
R&D expenditure, % of net sales	90.9%	117.3%		67.9%	69.1%		85.8%
Equity ratio, %	88.0%	79.6%		88.0%	79.6%		84.3%
Return on equity, %	-25.1%	-39.0%		-33.8%	-48.2%		-97.3%
Cash and cash equivalents	12,022	11,467	4.8%	12,022	11,467	4.8%	4,126
Earnings per share (undiluted)	-0.003	-0.17		-0.01	-0.23		-0.34
Earnings per share (diluted)	-0.002	-0.13		-0.003	-0.17		-0.28
Number of shares at the end of the period	1,341,785,963	30,783,092		1,341,785,963	30,783,092		30,788,092
Number of shares (diluted)	1,527,790,429	33,821,751		1,527,790,429	33,821,751		33,821,751
Number of personnel at the end of period	58	57	1.8%	58	57	1.8%	60

1From Q1/2026, the company has transitioned to reporting adjusted sales margin to be aligned with industry reporting standards. The adjusted sales margin describes the profitability of implant sales before commercialization-related expenses, such as sales commissions. Adjusted sales margin comprises the net sales of implants deducted by related cost of sales and extraordinary expenses. Items recognized below the adjusted sales margin will include, among others, commissions and external services considered fixed in nature.

Net sales by geographical area

EUR 1,000	4–6/2026	4–6/2025	Change, %	1–6/2026	1–6/2025	Change, %	1–12/2025
Europe	345	210	63.9%	779	353	120.3%	887
The U.S.	305	131	133.6%	597	184	225.2%	488
Rest of the world	449	337	33.5%	944	1,537	-38.6%	2,146
Total	1,100	678	62.2%	2,320	2,074	11.9%	3,522

Significant events in April–June 2026

On April 2, Bioretec published an exemption document relating to its rights issue.
On April 20, Bioretec published the notice to the Annual General Meeting to be held on May 8, 2026.
On April 23 and April 24, Bioretec published the preliminary and final results of the rights issue, respectively. The final results of the rights issue show that a total of 1,286,801,534 new shares were subscribed for in the offering, corresponding to approximately 87.1 per cent of the 1,477,828,416 new shares offered in the offering. The subscription price in the offering was EUR 0.01 per new share. Bioretec received gross proceeds of approximately EUR 12.9 million from the offering.
On April 28, Bioretec announced that 1,286,801,534 new shares subscribed for in the rights issue and 24,196,337 new shares issued to Stephen Industries Inc Oy as an underwriting fee pursuant to the underwriting commitment have been registered with the Trade Register maintained by the Finnish Patent and Registration Office. In addition, Bioretec announced that it would adjust the terms and conditions of its stock option programs due to the completed rights issue.
On May 8, Bioretec announced the resolutions of the Annual General Meeting and the constitutive meeting of the Board of Directors held on the same date.
On May 13, Bioretec announced that it clarifies its 2026–2028 financial target regarding the sales margin to concern the adjusted sales margin.
On June 1, Bioretec announced that it initiates new change negotiations in production to enhance operational efficiency. The change negotiations were concluded on June 17.
On June 1, Bioretec announced that its Board of Directors has resolved on a new stock option plan.
On June 17, Bioretec announced the appointment of Conan Cavanagh as Head of Research & Development and member of the Management Team.

Significant events after the reporting period

On July 2, Bioretec announced that Chief Financial Officer Tuukka Paavola will leave the company with immediate effect. The duties of the Chief Financial Officer will be assumed on an interim basis by Controller Anna-Mari Venola.
On August 5, Bioretec announced the appointment of Panu Mikkonen (M.Sc. Econ.) as Chief Financial Officer, effective 6 October 2026. In this role, Mikkonen will report to Chief Executive Officer Sarah van Hellenberg Hubar-Fisher and will join the company's Management Team.

CEO Sarah van Hellenberg Hubar-Fisher’s comments

H1 close signals momentum

In the second quarter, our commercial momentum continued by growing net sales by 62% to EUR 1.1 million. We achieved 133% year-over-year growth in the U.S. and 63% in Europe, demonstrating consistent volume growth and representation of market demand across targeted geographies. Our revenue base continues to reflect deliberate diversification through a broader mix of customers and distribution partners across key markets, reducing concentration risk and strengthening the quality of revenue. This is also reflected as improvements in the adjusted sales margin.

Alongside our commercial progress, we maintained a strong focus on cost discipline and operational efficiency. These results continue to signal the impact of the significant strategic adjustments made in 2025 and provide the foundation for sustainable long-term growth. Commercial growth combined with disciplined execution will be key to further improving the scalability of our business.

Expansion of the RemeOs™ platform remains a priority

Our strategy for 2026–2028 prioritizes disciplined execution, capital efficiency, and continued innovation through the expansion of the RemeOs™ platform. In research and development, our focus is on progressing the near-term product pipeline and expanding our patent portfolio across all three distinct materials, addressing a broader range of clinical needs in upper and lower extremities. In early development, we continue to progress our preclinical efforts for our spine portfolio, demonstrating further breadth of indication expansion and material performance with our hybrid composite.

Whilst we secure our future position with the continued development of material expertise and experience, we must also strengthen our focus on evidence generation through reputable clinical studies and related publications that demonstrate the value of our breakthrough claims.

To support us on this path, we announced the appointment of Conan Cavanagh as Head of Research & Development, effective as of 1 September 2026. Conan will be responsible for our R&D strategy, product portfolio management, and the execution of the product development program. We are confident that his experience will support the execution of our strategy, technology development and international growth. In addition, our former CTO Timo Lehtonen will continue his contributions toward our world class materials science leadership, technology expertise and strategy as an External Executive Advisor.

Discipline and Delivery

The results from the first half of this year represent a focus on discipline to drive deliverables. Across all functions of the business, our priorities and processes remain under scrutiny, ensuring that resourcing is allocated appropriately and effectively and the spirit of execution remains in service of a high performing organization. As we build our category leadership position further, we continue to set the foundation for a commercially robust and scalable business in high-value markets with repeatable demand drivers.

To achieve this, we will invest in strengthening our market presence and visibility across key markets, driving excellence in defined measures of success per market such as repeat surgeon utilization, consistent growth targets, industry defining publications, and expansion of the RemeOs™ product line.

The first two quarters of 2026 have provided clear signals that our strategy and commercial investments are translating into measurable results. We carry this momentum and increased confidence into the rest of 2026, with a continued commitment to defining our position as a category leader and delivering on our promise of patient outcomes that represent the best in material science where Biology meets Bone.

Financial reporting in 2026

In 2026, Bioretec will publish the following financial reports:

Business review for January–September 2026 on Thursday, November 12, 2026

The releases will be published as company releases and will be available online on Bioretec’s website at https://investors.bioretec.com/en/reports_and_presentations.

Tampere, August 13, 2026

Board of Directors

Bioretec Ltd

For additional information:

Sarah van Hellenberg Hubar-Fisher

CEO

+31 6 1544 8736

sarah.hubar-fisher@bioretec.com

Certified Adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

The company’s latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.

Bioretec’s Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.

Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit www.bioretec.com

Bioretec Half-year report 2026.pdf

by Admin

Panu Mikkonen appointed as Chief Financial Officer of Bioretec

ViewReleaseInStandardHtml

Panu Mikkonen appointed as Chief Financial Officer of Bioretec

Bioretec Ltd | Company announcement | 5 August 2026 at 4:00 p.m. EEST

Bioretec Ltd, a pioneer in absorbable orthopedic implants, appoints Panu Mikkonen (M.Sc. Econ) as Chief Financial Officer, effective 6 October 2026. In this role, Mikkonen will report to Chief Executive Officer Sarah van Hellenberg Hubar-Fisher and will join the company's management team.

Panu Mikkonen brings nearly 30 years of experience in finance, business controlling, corporate development, and strategic leadership across international organizations. Most recently, he has served as CFO of BPW Kraatz Group, where his responsibilities have included finance and IT operations in Finland and the Baltic states, while acting as a strategic partner to the management and the Board. During his career, Mikkonen has also held senior finance leadership roles at Atoy Group and Nordcloud Group.

Mikkonen holds a master’s degree in economics and business administration (accounting) from the Helsinki School of Economics. In his new role, he will oversee all financial operations, including financial planning, reporting, treasury, compliance, and investor relations, while supporting Bioretec’s continued international growth and long-term value creation.

“I am excited to join Bioretec at such an important stage of the company’s development. Bioretec has a unique position in the global orthopedic market, and I look forward to working with the team to support the company’s growth, strengthen its financial foundation, and create long-term value for patients, customers, and shareholders,” says Mikkonen.

“We are delighted to welcome Panu to Bioretec. He brings extensive experience in international finance leadership, business transformation, and value creation, which will be highly valuable as we continue to execute our growth strategy and expand globally. Panu joins us at an exciting stage in Bioretec’s journey, and we look forward to his contributions in helping us achieve our strategic objectives,” says CEO Sarah van Hellenberg Hubar-Fisher.

Further enquiries

Sarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736

Certified Adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

The company’s latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.

Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit www.bioretec.com

by Admin

Correction: The Board of Directors of Bioretec Ltd resolved on a new stock option plan

ViewReleaseInStandardHtml

Correction: The Board of Directors of Bioretec Ltd resolved on a new stock option plan

Bioretec Ltd Company Announcement 7 July 2026 at 6:55 p.m. EEST

Bioretec Ltd corrects its release concerning the decisions of its Board of Directors on a new stock option plan on 1 June 2026 at 7.05 p.m. EEST. The split between the stock options marked with the symbol 2026A and 2026B was incorrect.

Incorrect information:

Number of stock options marked with the symbol 2026A: 96,059,674

Number of stock options marked with the symbol 2026B: 86,911,133

Correct information:

Number of stock options marked with the symbol 2026A: 97,584,430

Number of stock options marked with the symbol 2026B: 85,386,377

Otherwise, the content of the release remains unchanged, and the corrected release is presented in full below:

The Board of Directors of Bioretec ltd resolved on a new stock option plan

The Board of Directors of Bioretec Ltd has resolved to establish a new stock option plan for key personnel and selected consultants of the Group. There is a weighty financial reason for the Company to issue stock options, as they are intended to form part of the incentive and commitment program for the Group’s key personnel and consultants. The stock options are intended to encourage the participants to work on a long-term basis to increase shareholder value and to commit the participants to the service of the Company. The stock option plan is directed to approximately 30 key persons and consultants.

A maximum total of 182,970,807 stock options will be issued, entitling their owners to subscribe for a maximum total of 182,970,807 new shares in the Company or existing shares held by the Company. The stock options are issued gratuitously. Of the stock options, 97,584,430 are marked with the symbol 2026A and 85,386,377 are marked with the symbol 2026B.

The shares to be subscribed for on the basis of the issued stock options correspond to a maximum total of 12 per cent of all the shares and votes in the Company after potential share subscriptions, should new shares be issued in the subscription. As a result of the share subscriptions, the number of shares in the Company may increase by a maximum total of 182,970,807 shares, should new shares be issued in the subscription.

The stock options vest gradually over four years, subject to continued employment or service. After a 12-month cliff, 40 per cent of the 2026A options and 25 per cent of the 2026B options will vest. The remaining options of both classes will vest in equal quarterly instalments over the subsequent three years.

The share subscription price for stock options 2026A and 2026B is the volume-weighted average share price (VWAP) of the Company’s share during the period of one (1) month commencing on April 29, 2026, plus a 20 per cent premium.

The share subscription price will be credited to the reserve for the Company’s invested unrestricted equity. The share subscription price will be reduced by the amount of dividends and assets from reserves of unrestricted equity per share resolved after the Board’s resolution but before the share subscription.

The share subscription period for the stock options starts when options vest and ends on May 31, 2032, for both stock options 2026A and 2026B.

The theoretical market value of one stock option is EUR 0.0172 per stock option. The total theoretical market value of all stock options is approximately EUR 3,147,098. The theoretical market value of one stock option has been calculated using the Black & Scholes stock option pricing model, taking into account the exercise price of the stock option and the following assumptions: share price EUR 0.0226, risk-free interest rate 2.77%, time to maturity approximately six years, current dividend yield 0% and volatility approximately 89.60%.

The Board of Directors resolved on the new stock option plan by virtue of an authorisation granted by the Extraordinary General Meeting of Shareholders on March 27, 2026.

Contacts

Kustaa Poutiainen, Chairperson of the Board, +358 40 042 4506

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

The company’s latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.

Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit www.bioretec.com

wkr0006.pdf

by Admin

Inside information: Chief Financial Officer Tuukka Paavola will leave the company

ViewReleaseInStandardHtml

Inside information: Chief Financial Officer Tuukka Paavola will leave the company

Bioretec Ltd, Inside Information, 2 July 2026 at 14.30 EEST

Bioretec Ltd and Tuukka Paavola have mutually agreed that Paavola will not continue in his position. Paavola will leave his role with immediate effect. The duties of the Chief Financial Officer will be assumed on an interim basis by Controller Anna-Mari Venola until a new Chief Financial Officer is appointed.

Bioretec will immediately initiate the recruitment process for a new Chief Financial Officer.

Paavola started in the position on January 20, 2026.

Bioretec thanks Tuukka Paavola for his contribution as Chief Financial Officer and wishes him success in his future endeavors.

Further enquiries

Sarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025.

Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients.

Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit www.bioretec.com

by Admin

Bioretec appoints Conan Cavanagh as Head of Research & Development and member of the Management Team

ViewReleaseInStandardHtml

Bioretec appoints Conan Cavanagh as Head of Research & Development and member of the Management Team

Bioretec Ltd | Press Release | 17 June 2026 at 16:00 EEST

Bioretec Ltd, a pioneer in absorbable orthopedic implants, has appointed Conan Cavanagh as Head of Research & Development and as a member of the management team as of 1 September 2026. Cavanagh will report directly to CEO Sarah van Hellenberg Hubar-Fisher.

Conan Cavanagh has over 25 years of experience in the development of medical devices, biomaterials, and product commercialization. He currently serves as Chief Operating Officer and Head of Research & Development at HidraMed Solutions. Previously, among other positions, he has served as Engineering Director at Smith & Nephew, where he was broadly responsible for the development and commercialization of orthopedic and sports medicine products.

Cavanagh has a bachelor’s degree in biomedical engineering and also holds a master’s degree in management. He has extensive experience across the full lifecycle of product development, from concept generation to commercialization. In addition, he has deep expertise in clinical studies, regulatory processes and intellectual property management.

In his new role at Bioretec, Cavanagh will be responsible for the company’s research and development strategy, management of the product portfolio, and the execution of the product development program. He will have a central role in strengthening Bioretec’s technological development, clinical evidence and regulatory readiness, as well as in supporting the company’s long-term growth and international competitiveness.

“I am very pleased to be joining Bioretec’s team at this important stage and to have the opportunity to advance the company’s growth through innovation and new technology,” says Conan Cavanagh.

“We are thrilled to welcome Conan Cavanagh to Bioretec. We look forward to his leadership and input as we continue on our mission to become the global market leader in absorbable orthopedic implants. Conan joins us at a pivotal and exciting stage in the company’s development, and we are excited to see his significant contribution to executing our strategy, advancing our technology and supporting our international growth,” says CEO Sarah van Hellenberg Hubar-Fisher.

Further enquiries

Sarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit www.bioretec.com

by Admin

Bioretec appoints Conan Cavanagh as Head of Research & Development and member of the Management Team

ViewReleaseInStandardHtml

Bioretec appoints Conan Cavanagh as Head of Research & Development and member of the Management Team

Bioretec Ltd | Press Release | 17 June 2026 at 16:00 EEST

Further enquiries

Sarah van Hellenberg Hubar-Fisher, CEO, +31 6 1544 8736

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit www.bioretec.com

by Admin

Bioretec concludes change negotiations

ViewReleaseInStandardHtml

Bioretec concludes change negotiations

Bioretec Ltd, Press Release, 17 June 2026 at 9:00 EEST

On 1 June 2026, Bioretec announced the initiation of change negotiations in accordance with the Finnish Act on Co-operation within Undertakings, focusing on the company’s production function in Finland. The aim of the negotiations was to streamline operations and consequently to improve the company’s competitiveness and profitability.

The negotiations began on 8 June 2026 and were concluded today.

At the start of the negotiations, the company estimated that the plans may impact the terms of employment of up to four individuals in Finland. As a result of the negotiations, the employment of three employees will be terminated.

A total of 12 employees from Bioretec’s staff in Finland were included in the scope of the negotiations.

Further enquiries

Tuukka Paavola, CFO, +358 50 386 0013

Information about Bioretec

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit www.bioretec.com

by Admin

Bioretec Ltd – Manager’s transactions – van Hellenberg Hubar-Fisher

ViewReleaseInStandardHtml

Bioretec Ltd – Manager’s transactions – van Hellenberg Hubar-Fisher

Bioretec Ltd Company release 4 June 2026 at 14:25 p.m. EEST

Bioretec Ltd - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Sarah van Hellenberg Hubar-Fisher

Position: Chief Executive Officer

Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 159307/6/8

____________________________________________

Transaction date: 2026-06-02

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000480454

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 1660000 Unit price: 0.02258 EUR

Aggregated transactions (1):

Volume: 1660000 Volume weighted average price: 0.02258 EUR

Further enquiries

Tuukka Paavola, CFO, +358 50 386 0013

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit www.bioretec.com

by Admin

Bioretec Ltd – Manager’s transactions – Jordy Winters

ViewReleaseInStandardHtml

Bioretec Ltd – Manager’s transactions – Jordy Winters

Bioretec Oy Company release 2 June 2026 at 13:25 p.m. EEST

Bioretec Oy - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Jordy Winters

Position: Other senior manager

Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 158959/6/4

____________________________________________

Transaction date: 2026-05-29

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)

Instrument type: SHARE

ISIN: FI4000480454

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 50000 Unit price: 0.0224 EUR

(2): Volume: 109000 Unit price: 0.0224 EUR

(3): Volume: 82596 Unit price: 0.0224 EUR

(4): Volume: 2849 Unit price: 0.0224 EUR

(5): Volume: 200000 Unit price: 0.0224 EUR

(6): Volume: 555555 Unit price: 0.0224 EUR

Aggregated transactions (6):

Volume: 1000000 Volume weighted average price: 0.0224 EUR

Further enquiries

Tuukka Paavola, CFO, +358 50 386 0013

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit www.bioretec.com

by Admin

The Board of Directors of Bioretec Ltd resolved on a new stock option plan

ViewReleaseInStandardHtml

The Board of Directors of Bioretec Ltd resolved on a new stock option plan

Bioretec Ltd Company Announcement 1 June 2026 at 19:05 p.m. EEST

THE BOARD OF DIRECTORS OF BIORETEC LTD RESOLVED ON A NEW STOCK OPTION PLAN

The Board of Directors of Bioretec Ltd has resolved to establish a new stock option plan for key personnel and selected consultants of the Group. There is a weighty financial reason for the Company to issue stock options, as they are intended to form part of the incentive and commitment program for the Group's key personnel and consultants. The stock options are intended to encourage the participants to work on a long-term basis to increase shareholder value and to commit the participants to the service of the Company. The stock option plan is directed to approximately 30 key persons and consultants.

A maximum total of 182,970,807 stock options will be issued, entitling their owners to subscribe for a maximum total of 182,970,807 new shares in the Company or existing shares held by the Company. The stock options are issued gratuitously. Of the stock options, 96,059,674 are marked with the symbol 2026A and 86,911,133 are marked with the symbol 2026B.

The share subscription price for stock options 2026A and 2026B is the volume-weighted average share price (VWAP) of the Company's share during the period of one (1) month commencing on April 29, 2026, plus a 20 per cent premium.

The share subscription price will be credited to the reserve for the Company's invested unrestricted equity. The share subscription price will be reduced by the amount of dividends and assets from reserves of unrestricted equity per share resolved after the Board’s resolution but before the share subscription.

The share subscription period for the stock options starts when options vest and ends on May 31, 2032, for both stock options 2026A and 2026B.

The Board of Directors resolved on the new stock option plan by virtue of an authorisation granted by the Extraordinary General Meeting of Shareholders on March 27, 2026.

Contacts

Kustaa Poutiainen, Chairperson of the Board, +358 40 042 4506

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries.

Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions.

To learn more about Bioretec, visit www.bioretec.com

by Admin